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Abstract
Background
The contribution of 5α-reductase 1 and 5α-reductase 2 to prostate cancer development and
progression is not clearly understood. TRAMP mice are a common prostate cancer model,
in which 5α-reductase 1 and 5α-reductase 2 expression levels, along with prostate lesions
scores, have not been investigated at different time points to further understand prostate
carcinogenesis.
Method/Principal findings
To this end, 8-, 12-, 16-, and 20-week-old male C57BL/6TRAMP x FVB mice prostate most
severe and most common lesion scores, 5α-reductase 1 and 5α-reductase 2 in situ hybrid-
ization expression, and Ki-67, androgen receptor, and apoptosis immunohistochemistry
levels were measured. Levels of these markers were quantified in prostate epithelium,
hyperplasia, and tumors sections. Mice developed low- to high-grade prostatic intraepithelial
neoplasia at 8 weeks as the most severe and most common lesions, and moderate- and
high-grade prostatic intraepithelial neoplasia at 12 and 16 weeks as the most severe lesion
in all lobes. Moderately differentiated adenocarcinoma was observed at 20 weeks in all
lobes. Poorly differentiated carcinoma was not observed in any lobe until 12-weeks-old. 5α-
reductase 1 and 5α-reductase 2 were not significantly decreased in tumors compared to
prostate epithelium and hyperplasia in all groups, while proliferation, apoptosis, and andro-
gen receptor were either notably or significantly decreased in tumors compared with pros-
tate epithelium and hyperplasia in most or all groups. Prostate 5αR1 levels were positively
correlated with adjusted prostate most severe lesion scores.
Conclusion
Downregulation of androgen receptor and 5α-reductase 2, along with upregulation of 5α-
reductase 1 in tumors may promote prostatic intraepithelial neoplasia and prostate cancer
development in TRAMP mice.
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Introduction
Among US men, prostate cancer is the most commonly diagnosed cancer and the third-lead-
ing cause of cancer death [1]. Androgens are primarily involved in the development and pro-
gression of prostate cancer [2]. Testosterone is converted by the isoenzymes 5α-reductase 1
(5αR1) and 5α-reductase 2 (5αR2) into dihydrotestosterone to regulate the prostate gland
[3,4]. Androgens bind to the androgen receptor (AR), with the latter acting as a transcription
factor to regulate the expression of androgen response genes that modulate many cellular
activities such as proliferation and apoptosis to contribute to prostate cancer development and
progression [5]. In the normal prostate, 5α-reductase 2 is the primary isoenzyme [6].
Many studies [7–10] although not all [11–13], have observed increased 5α-reductase 1 and/
or decreased 5α-reductase 2 mRNA expression or activity in prostate cancer compared with
nonmalignant prostate tissue. Additionally, 5α-reductase 1 and 5α-reductase 2 were observed
in 73% and 56%, respectively, of human prostate cancer tissues [12]. Taken together, 5α-
reductases may be involved in prostate carcinogenesis [14].
A common model is the transgenic mouse model (TRAMP), which uses the rat prostate-
specific promoter probasin to direct the expression of the simian virus 40 (SV40) large and
small T antigen to the prostate epithelium to cause cell transformation. TRAMP mice develop
progressive forms of prostate cancer with lesions ranging from mild prostatic intraepithelial
neoplasia (PIN) through well-differentiated (WD) adenocarcinoma, to invasive PD adenocar-
cinoma with distant site metastasis to pelvic lymph nodes and lungs [15,16]. In TRAMP mice,
the transgene is detected as early as 3 weeks of age [17], with pathological features similar to
low-grade PIN developing as early as 4–6 weeks of age [18]. C57BL/6 TRAMP x FVB mice
develop epithelial hyperplasia by 8 weeks [19], PIN and WD adenocarcinoma by 12 weeks,
and invasive carcinoma appearing between 18–30 weeks and metastasizing into lymph nodes
and lungs and occasionally kidney, bone and adrenal glands [18,20]. By 30 weeks of age,
TRAMP mice on an FVB background (TRAMP x FVB) display 100% metastasis to lungs and
lymph nodes along with bone metastasis [16,21].
In addition to not understanding 5α-reductase levels in TRAMP mice, modified grading
schemes [22] have not been employed to assess the development and progression of prostate
cancer in these mice. Thus, this study was designed to quantify the cell-type specific expression
patterns of 5αR1 and 5αR2 mRNA, AR and Ki-67 protein, along with apoptotic DNA fragmen-
tation, in prostate tissue sections of 8-, 12-, 16-, and 20-week-old C57BL/6 TRAMP x FVB mice
to characterize how their levels vary at different ages and stages of prostate carcinogenesis. Six-
teen weeks is intermediate between 12 and 20 weeks when TRAMP mice would have developed
PD and invasive carcinoma [20]. These time points were used previously to study the incidence
and distribution of pathologic changes within each lobe of C57BL/6 TRAMP x FVB mice pros-
tate as a function of time [20]. To the best of our knowledge, this study is the first to grade
lesions and quantify 5α-reductase levels at different ages in TRAMP mouse prostate.
Materials and methods
Ethics statement
The Institutional Animal Care and Use Committee (IACUC) at Kansas State University
approved all animal procedures (protocol 2969).
Study mice and design
Mice were bred as described previously [23]. Male C57BL/6 TRAMP x FVB mice were weaned
and began consuming AIN-93G diet at 3 weeks of age before being randomized to 8- (n = 5),
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12- (n = 8), 16- (n = 9), and 20- (n = 12) week groups. Mice were cohoused until 8 weeks, and
then individually housed, monitored daily, weighed weekly, and provided AIN-93G diet and
water ad libitum. Mice were terminated at their respective study time points by anesthetizing
via CO2 inhalation and euthanized by exsanguination. The genitourinary (GU) tracts, kidneys,
and lungs were dissected, and the GU tracts were weighed. Iliac lymph nodes were also col-
lected whenever possible. All tissues were fixed by immersion in 10% neutral buffered formalin
for 48 hours, and then moved to 70% alcohol until processing in the Kansas State University
Veterinary Diagnostic Laboratory.
Histopathology
Histological processing of prostate tissues, sectioning, scoring for most common and most
severe lesions, and adjusting for distribution, were performed as described previously [22,23].
The anterior, dorsal, lateral and ventral lobes of C57BL/6 TRAMP × FVB mice were assigned
two grades each between 0–7. The first grade is the most severe lesion within the lobe [normal
prostate as least severe (grade 0), and PD carcinoma as most severe (grade 7)]. The second
grade is the most common lesion within the lobe [normal prostate as least common (grade 0),
and PD carcinoma as most common (grade 7)]. The most severe and most common lesions
within a lobe were adjusted for distribution, either as focal, multifocal, or diffuse. With focal,
there are fewer than three foci within the lobe. Multifocal indicates there are three or more foci
within the lobe, with less than 50% of the lobe containing the lesion of interest. Diffuse indi-
cates greater than 50% of the lobe is affected [23]. Prostate lesions were scored blindly twice by
a board-certified pathologist (JNH). Select tissues were also scored blindly twice by a board-
certified second veterinary pathologist (APB) to ensure scoring consistency. Iliac lymph nodes
examination for metastases was done as described previously [23]. Formalin-fixed, paraffin-
embedded prostate tissue sections (4 μm) of 8-, 12-, 16-, and 20-week-old (n = 5) AIN-93G-
fed male C57BL/6 TRAMP x FVB mice were prepared for biomarker detection. Most prostate
samples at the time of euthanasia were completely obliterated by tumor and therefore in most
samples, prostate lobes could not be identified. In some instances, all four lobes were replaced
by tumor.
5α-reductase 1 and 5α-reductase 2 in situ hybridization
5αR1 and 5αR2 accessions NM 175283.3 and NM 053188.2, respectively, obtained from
National Center for Biotechnology Information (NCBI) website were submitted to Advanced
Cell Diagnostics, Inc., [(ACD), Hayward, CA)] for custom probe design and synthesis for use
in their RNAscope assay. Prostate sections were baked in a Fisher Scientific (model 77) slide
warmer preheated to 55˚C for 25 minutes. Sections were deparaffinized in xylene, rehydrated
in 100% ethanol, and air-dried for 5 minutes at room temperature. Sections were then treated
serially with: Pre-Treatment 1 solution (endogenous hydrogen peroxidase block with Pretreat
1 solution for 10 minutes at room temperature); Pre-Treatment 2 (100–104˚C, 25 minutes
immersion in Pretreat 2 solution); and, Pre-Treatment 3 (protease digestion, 40˚C for 28 min-
utes); rinses with distilled water (2X) were performed after each Pre-Treatment step. Sections
were then hybridized in 5αR1 or 5αR2 probes, without a cover slip, at 40˚C for 2 hours in a
HybEZ Oven (ACD). After wash buffer steps, signal amplification from the hybridized probes
were performed by the serial application of Amp 1, 40˚C for 30 minutes (PreAmplifier step);
Amp 2, 40˚C for 15 minutes (signal enhancer step); Amp 3, 40˚C for 30 minutes (amplifier
step); Amp 4, 40˚C for 15 minutes (Label Probe step); Amp 5, ambient temperature for 30 min-
utes, and Amp 6, ambient temperature for 15 minutes (signal amplifications steps). Wash
buffer steps with Wash Buffer (ACD, proprietary) were performed after each Amp step.
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Horseradish peroxidase (HRP) activity was then observed by the application of 3,30-diamino-
benzidine (DAB) for 10 minutes at ambient temperature. Sections were then counterstained
with Gill’s hematoxylin, dehydrated through graded ethanol [95% (1X) and 100% (2X)] and
xylene and then mounted. Sections were quality controlled for RNA integrity with an RNA-
scope probe for cyclophilin B (Mm-Ppib) RNA (positive control) and for nonspecific back-
ground with a probe for bacterial dapB RNA (negative control). Specific RNA staining signal
was identified as brown, punctate dots.
Immunohistochemistry
Androgen receptor. Prostate sections were baked in a Fisher Scientific Isotemp (model
281A) vacuum oven preheated to 60˚C for 30 minutes. After baking, sections were deparaffi-
nized in xylene and rehydrated using a decreasing ethanol gradient [100% (2X), 95% and 80%
(1X)]. Endogenous alkaline phosphatase was blocked using 3% hydrogen peroxide in metha-
nol. Antigen retrieval was carried out by microwaving at 540W in 10 mM Tris/1 mM EDTA
buffer, pH 9, four times for 5 minutes. Sections were blocked with 2.5% normal horse serum
(Vector Laboratories, Inc., Burlingame, CA) before incubation for 1 hour at 37˚C with a rabbit
polyclonal antibody to AR (1:50 dilution; N-20, sc-816; Santa Cruz Biotechnology, Santa Cruz,
CA). After washing, sections were incubated with ImmPRESS-AP anti-rabbit IgG (alkaline
phosphatase) polymer detection reagent (MP-5401; Vector Laboratories, Inc.,) for 30 minutes
at room temperature. Colors were developed with a Vector Red alkaline phosphatase substrate
kit (SK-5100; Vector Laboratories, Inc.,). Slides were subsequently counterstained with hema-
toxylin (Vector Laboratories, Inc.,), and processed back to xylene through an increasing etha-
nol gradient [80% and 95% (1X), and 100% (2X)] and then mounted. Normal rabbit IgG
(1:100; sc-2027: Santa Cruz Biotechnology) was used as a negative control.
Ki-67. Prostate sections were deparaffinized in Leica Bond Dewax Solution (Leica Micro-
systems Inc., Buffalo Grove, IL) at 72˚C, and then rehydrated in 100% ethanol, followed by 3
washes in Tris-buffered saline. Antigen retrieval was carried out with Novocastra Bond Epitope
Retrieval Solution 1 (citrate buffer, pH 6) (AR9961; Leica Microsystems Inc.,) for 20 minutes
at 100˚C. The sections were stained with a prediluted rabbit monoclonal antibody to Ki-67
(CPRM325AA; Biocare Medicals, Concord, CA) for 15 minutes at room temperature. The anti-
rabbit poly-HRP-IgG polymer from the Bond Polymer Refine Detection System (Leica Micro-
systems Inc.,) was used for the enhancement of the signal. The substrate chromogen, DAB, was
used for the detection of the complex. Sections were counterstained with Gill’s hematoxylin,
and processed back to xylene through an increasing ethanol gradient [95% (1X) and 100%
(2X)], and then mounted. Tissue from a canine mast cell tumor was used as a positive control.
Apoptosis. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)
staining was performed using the Apoptag Peroxidase In Situ Apoptosis Detection kit (S7100;
Millipore, Temecula, CA). Prostate sections were baked in a Fisher Scientific Isotemp (model
281A) vacuum oven preheated to 60˚C for 30 minutes. After baking, sections were deparaffi-
nized in xylene, rehydrated through a graded ethanol series [100% (2X), 95% and 70% (1X)]
and treated with ready-to-use proteinase K (S302080-2; Dako North America, Inc., Carpin-
teria, CA) for 15 minutes at room temperature. Sections were washed with 2 changes of dis-
tilled water for 5 minutes each. Endogenous peroxidases were blocked with 3% hydrogen
peroxide in phosphate buffered saline (PBS, pH 7.4), for 5 minutes and washed with 2 changes
of PBS. Equilibration buffer containing digoxigenin-conjugated nucleotides was placed di-
rectly onto the section for 10 seconds. Sections were incubated with terminal deoxynucleotide
transferase (TdT) enzyme (1:15 dilution) in a humidified chamber at 37˚C for 1 hour. Sections
were then incubated for 10 minutes at room temperature in stop-wash buffer, rinsed in 3
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changes of PBS for 1 minute each, and then incubated with anti-digoxigenin conjugate for 30
minutes at room temperature. Sections were washed in 4 changes of PBS for 2 minutes each,
and then incubated with the substrate chromogen, DAB, for 3 minutes. Sections were then
stained with 0.5% (w/v) methyl green counterstain, dehydrated through 100% N-butanol (3X)
and xylene and then mounted.
Biomarker quantification
A board-certified pathologist identified areas of epithelium that were composed of a single
layer of cells as prostate epithelium; hyperplastic regions as where there was increased density
of cells piled up on one another; and tumor as diffuse sheets of cells with no organization char-
acterized by neoplastic cellular characteristics, using an Olympus DP26 digital camera (Olym-
pus America, Center Valley, PA). These areas were scanned using a Pannoramic Midi scanner
(3D Histech, Budapest, Hungary) with a 20X objective, giving 2-megapixel resolution. Images
were captured using the 3D Histech software. Scanned images were then annotated using Halo
software (Indica Laboratory, Coralles, NM). In tumors, areas of viable neoplastic cells away
from areas of necrosis were measured. Ki-67 and AR protein, and apoptotic DNA fragmenta-
tion were quantified using the double stain cytoplasmic and nuclear immunohistochemistry
algorithm (Indica Laboratory), which was set to identify a single positive nuclear stain. 5αR1
and 5αR2 mRNA were quantified using the chromogenic RNA in situ hybridization algorithm
(Indica Laboratory), which measures RNA probes on a per cell basis. Data were quantified for
Ki-67, AR, apoptosis, 5αR1 and 5αR2 in prostate epithelium, hyperplasia, and tumor of pros-
tate sections. Prostate epithelium was defined as histologically normal prostate. Representative
images in Fig 1 were captured at 2X magnification.
The total positive cells per tissue area for Ki-67, AR and apoptosis was calculated as:
Total positive cells per tissue area (μm2) = Total positive cells/Tissue area (μm2)
The total probe copies per tissue area for 5αR1 and 5αR2 mRNA was calculated as:
Total probe copies per tissue area (μm2) = Total probe copies/Total tissue area (μm2)
Total pixels per tissue area for 5αR1 and 5αR2 mRNA was also calculated, but this was not
used for data analysis due to poor sensitivity. Immunohistochemistry and in situ hybridization
data are from a single experiment for each biomarker.
Statistical analysis
Data were analyzed using ANOVA with Fisher’s Least Significant Difference (LSD), utilizing SAS
9.4 (SAS Institute Inc., Cary, NC) with p< 0.05 considered statistically significant. Cell types with
n< 2 were excluded from statistical analysis, and the modified Thompson tau technique was
used to eliminate outliers. Iliac lymph node metastases incidence was analyzed using the Kruskal
Wallis non-parametric one-way ANOVA. Correlation between biomarkers and adjusted prostate
severe lesion scores was analyzed using the Spearman rank correlation coefficient (r).
Results
GU weights and iliac lymph node metastases
GU weights in 8-, 12-, 16-, and 20-week-old C57BL/6 TRAMP x FVB mice were increased as a
function of age (Table 1). Twenty-week-old mice had significantly increased GU weights
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Fig 1. Representative staining for 5α-reductase 1 (a), 5α-reductase 2 (d), androgen receptor (g), Ki-67 (j) and
apoptosis (m) in prostate epithelium showing single layer of cells; 5α-reductase 1 (b), 5α-reductase 2 (e),
androgen receptor (h), Ki-67 (k) and apoptosis (n) in hyperplasia showing focal increased cell density with
piling up on one another; and 5α-reductase 1 (c), 5α-reductase 2 (f), androgen receptor (i), Ki-67 (l) and
apoptosis (o) in tumor showing diffuse sheets of cells with no organization and characterized by neoplastic
cellular characteristics. Staining in prostate and hyperplasia are shown with a black arrow.
https://doi.org/10.1371/journal.pone.0175874.g001
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versus 8-, 12-, and 16-week-old mice. No significant differences were observed in the incidence
of iliac lymph node metastases between groups (Table 1); however, a notable difference was
found in incidence between 20- (42%) and 16- (11%), 12- (0%) and 8- (0%) week-old mice.
Most severe and most common lesion scores and histopathological
distribution
Anterior and dorsal lobes raw and adjusted mean most severe and most common lesion scores
were significantly increased in 20- versus 8-, 12-, and 16-week-old mice (Tables 2 and 3). The
dorsal lobe adjusted mean most common lesion score was significantly increased in 16- com-
pared to 12-week-old mice. Lateral and ventral lobes raw and adjusted mean most severe and
most common lesion scores were significantly increased in 16- and 20- versus 8- and 12-week-
old mice.
Anterior lobe LG-PIN as the most severe lesion was significantly increased in 8- versus
12- and 20-week-old mice (Table 4). LG-PIN as the most severe lesion was significantly in-
creased in the ventral lobe of 8- compared to 16- and 20-week-old mice. Lateral lobe moder-
ate-grade (MG) PIN as the most severe lesion was significantly increased in 8- versus 12-week-
old, and in 8- and 12- compared to 16- and 20-week-old mice. MG-PIN as the most severe
lesion was significantly increased in the ventral lobe of 8- versus 12-, 16-, and 20-week-old
mice. MG-PIN as the most severe lesion was significantly increased in the ventral lobe of 12-
and 16- compared to 20-week-old mice. Lateral lobe HG-PIN as the most severe lesion was
significantly increased in 12- and 16- versus 8- and 20-week-old mice. HG-PIN as the most
severe lesion was significantly increased in the ventral lobe of 12-week-old mice compared to
8- and 20-week-old mice. Dorsal lobe HG-PIN as the most severe lesion was significantly
increased in 12- and 16- versus 20-week-old mice. PD carcinoma and prostate cancer as the
most severe lesions were significantly increased in the anterior lobe of 20- compared to 8-, 12-,
and 16-week-old mice. Dorsal lobe PD carcinoma and prostate cancer as the most severe
lesions were significantly increased in 20- versus 8-, 12-, and 16-week-old mice. PD carcinoma
Table 1. C57BL/6 TRAMP x FVB mice GU weights1 and iliac lymph node metastases incidence.
Group n GU weights (g) n Lymph node
metastases incidence (%)
8-weeks 5 0.30 ± 0.01a 2 0 (0)
12-weeks 8 0.38 ± 0.02a 8 0 (0)
16-weeks 9 0.62 ± 0.07a 9 1 (11)
20-weeks 12 3.88 ± 1.09b 12 5 (42)
1Data are mean ± SEM; values with different letters are statistically different (p < 0.05).
https://doi.org/10.1371/journal.pone.0175874.t001
Table 2. Raw and adjusted mean most severe lesion scores for the anterior, dorsal, lateral, and ventral prostate lobes1.
Anterior prostate Dorsal prostate Lateral prostate Ventral prostate
Group n Raw Adjusted Raw Adjusted Raw Adjusted Raw Adjusted
8-weeks 5 2.10 ± 0.28a 4.10 ± 0.86a 2.50 ± 0.17a 6.10 ± 0.38a 1.90 ± 0.10a 4.80 ± 0.47a 1.60 ± 0.16a 4.30 ± 0.63a
12-weeks 8 2.56 ± 0.13a 6.13 ± 0.30a 3.00 ± 0.29a 7.38 ± 0.81a 3.00 ± 0.41a 7.50 ± 1.15a 1.56 ± 0.27a 3.56 ± 0.67a
16-weeks 9 2.39 ± 0.31a 5.78 ± 0.95a 3.78 ± 0.42a 10.17 ± 1.39a 5.17 ± 0.50b 14.44 ± 1.62b 4.83 ± 0.59b 13.66 ± 1.87b
20-weeks 12 4.92 ± 0.51b 14.21 ± 1.65b 5.63 ± 0.43b 16.33 ± 1.38b 5.42 ± 0.51b 15.88 ± 1.62b 4.86 ± 0.61b 14.18 ± 1.93b
1Data are mean ± SEM; values with different letters are statistically different from one another (p < 0.05).
https://doi.org/10.1371/journal.pone.0175874.t002
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and prostate cancer as the most severe lesions were significantly increased in the dorsal lobe of
16- compared to 8- and 12-week-old mice. Lateral and ventral lobes PD carcinoma and pros-
tate cancer as the most severe lesions were significantly increased in 16- and 20- versus 8- and
12-week-old mice. Prostate cancer as the most severe lesion was significantly increased in the
lateral and ventral lobes of 20- compared to 16-week-old mice.
Anterior lobe LG-PIN as the most common lesion was significantly increased in 8- versus
12- and 20-week-old mice (Table 5). MG-PIN as the most common lesion was significantly
increased in the anterior lobe of 12- compared to 8-, 16-, and 20-week-old mice. Dorsal lobe
MG-PIN as the most common lesion was significantly increased in 8- and 12- versus 16- and
Table 3. Raw and adjusted mean most common lesion scores for the anterior, dorsal, lateral, and ventral prostate lobes1.
Anterior prostate Dorsal prostate Lateral prostate Ventral prostate
Group n Raw Adjusted Raw Adjusted Raw Adjusted Raw Adjusted
8-weeks 5 1.30 ± 0.21a 2.70 ± 0.58a 2.0a 5.20 ± 0.13a,b 1.50 ± 0.17a 3.70 ± 0.65a 1.60 ± 0.16a 4.30 ± 0.63a
12-weeks 8 1.81 ± 0.14a 4.44 ± 0.41a 2.0a 5.50 ± 0.26a 1.63 ± 0.13a 4.25 ± 0.46a 1.25 ± 0.21a 3.13 ± 0.62a
16-weeks 9 1.83 ± 0.34a 4.56 ± 1.01a 3.22 ± 0.50a 9.39 ± 1.49b 4.11 ± 0.63b 11.94 ± 1.93b 4.22 ± 0.60b 12.28 ± 1.87b
20-weeks 12 4.83 ± 0.53b 14.04 ± 1.69b 4.75 ± 0.50b 14.00 ± 1.55c 5.21 ± 0.52b 15.25 ± 1.67b 4.77 ± 0.63b 14.09 ± 1.96b
1Data are mean ± SEM; values with different letters are statistically different from one another (p < 0.05).
https://doi.org/10.1371/journal.pone.0175874.t003
Table 4. Histopathological analysis (most severe lesion) of individual prostate lobes in 8-, 12-, 16-, and 20-week-old C57BL/6 TRAMP x FVB mice1, 2.
Prostatic intraepithelial neoplasia Adenocarcinoma Prostate cancer
n LG MG HG WD MD PD (WD-PD)
Anterior prostate
8-weeks 5 30%a 30% 40% 0% 0% 0%a 0%a
12-weeks 8 0%b 44% 56% 0% 0% 0%a 0%a
16-weeks 9 17%a,b 50% 28% 0% 0% 6%a 6%a
20-weeks 12 8%b 8% 17% 0% 4% 54%b 58%b
Dorsal prostate
8-weeks 5 0% 50% 50%a,b 0% 0% 0%a 0%a
12-weeks 8 0% 25% 69%a 0% 0% 6%a 6%a
16-weeks 9 0% 11% 67%a 0% 0% 22%b 22%b
20-weeks 12 0% 17% 13%b 0% 4% 67%c 71%c
Lateral prostate
8-weeks 5 10% 90%a 0%a 0% 0% 0%a 0%a
12-weeks 8 0% 50%b 38%b 0% 0% 13%a 13%b
16-weeks 9 0% 6%c 39%b 0% 0% 56%b 56%c
20-weeks 12 17% 4%c 8%a 0% 4% 67%b 71%d
Ventral prostate
8-weeks 5 40%a 60%a 0%a 0% 0% 0%a 0%a
12-weeks 8 13%a,b 44%b 19%b 0% 0% 0%a 0%a
16-weeks 9 0%b 39%b 6%a,b 0% 0% 56%b 56%b
20-weeks 12 8%b 17%c 0%a 0% 4% 54%b 58%c
1Values with different letters are statistically different from one another (p < 0.05).
2LG = low-grade, MG = moderate-grade, HG = high-grade, PIN = prostatic intraepithelial neoplasia, WD = well-differentiated, MD = moderately
differentiated, PD = poorly differentiated.
https://doi.org/10.1371/journal.pone.0175874.t004
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20-week-old mice. Ventral lobe MG-PIN as the most common lesion was significantly in-
creased in 8-, 12-, and 16- compared to 20-week-old mice. Dorsal lobe HG-PIN as the most
common lesion was significantly increased in 16- and 20- versus 8- and 12-week-old mice.
HG-PIN as the most common lesion was significantly increased in the dorsal lobe of 16- com-
pared to 20-week-old mice. Anterior and dorsal lobes PD carcinoma and prostate cancer as
the most common lesions were significantly increased in 20- versus 8-, 12- and 16-week-old
mice. PD carcinoma as the most common lesion was significantly increased in the dorsal lobe
of 20- compared to 16-week-old mice. PD carcinoma and prostate cancer as the most common
lesions were significantly increased in the lateral and ventral lobes of 20- versus 16-week-old
mice. Lateral and ventral lobes PD carcinoma and prostate cancer as the most common lesions
were significantly increased in 16- and 20- compared to 8- and 12-week-old mice.
5αR1, 5αR2, AR, proliferation, and apoptosis
Prostate epithelium, hyperplasia and tumor representative stainings for 5αR1 are shown in Fig
1A, 1B and 1C, respectively. Prostate epithelium, hyperplasia and tumor representative stain-
ings for 5αR2 are shown in Fig 1D, 1E and 1F, respectively. There was no significant difference
in 5αR1 and 5αR2 in the cell types within and between groups (Tables 6 and 7). 5αR1 was pre-
dominantly expressed in prostate epithelium versus stroma while 5αR2 was highly expressed
in both prostate epithelium and stroma. Prostate epithelium, hyperplasia and tumor AR repre-
sentative stainings are shown in Fig 1G, 1H and 1I, respectively. There was a significant
Table 5. Histopathological analysis (most common lesion) of individual prostate lobes in 8-, 12-, 16-, and 20-week-old C57BL/6 TRAMP x FVB
mice1, 2.
Prostatic intraepithelial neoplasia Adenocarcinoma Prostate cancer
n LG MG HG WD MD PD (WD-PD)
Anterior prostate
8-weeks 5 80%a 10%a 10% 0% 0% 0%a 0%a
12-weeks 8 25%b,c 69%b 6% 0% 0% 0%a 0%a
16-weeks 9 50%a,b 39%a 6% 0% 0% 6%a 6%a
20-weeks 12 13%c 21%a 8% 0% 4% 54%b 58%b
Dorsal prostate
8-weeks 5 0% 100%a 0%a 0% 0% 0%a 0%a
12-weeks 8 0% 100%a 0%a 0% 0% 0%a 0%a
16-weeks 9 0% 67%b 11%b 0% 0% 22%b 22%a
20-weeks 12 0% 38%b 8%c 0% 4% 50%c 54%b
Lateral prostate
8-weeks 5 50% 50% 0% 0% 0% 0%a 0%a
12-weeks 8 38% 63% 0% 0% 0% 0%a 0%a
16-weeks 9 11% 44% 0% 0% 0% 44%b 44%b
20-weeks 12 17% 8% 8% 0% 4% 63%c 67%c
Ventral prostate
8-weeks 5 40% 60%a 0% 0% 0% 0%a 0%a
12-weeks 8 25% 50%a 0% 0% 0% 0%a 0%a
16-weeks 9 0% 56%a 0% 0% 0% 44%b 44%b
20-weeks 12 17% 8%b 0% 0% 4% 54%c 58%c
1Values with different letters are statistically different from one another (p < 0.05).
2LG = low-grade, MG = moderate-grade, HG = high-grade, PIN = prostatic intraepithelial neoplasia, WD = well-differentiated, MD = moderately
differentiated, PD = poorly differentiated.
https://doi.org/10.1371/journal.pone.0175874.t005
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increase in AR expression in hyperplasia compared to prostate epithelium and tumor of
16-week-old mice (Table 8). There was a significant decrease in AR expression in tumor versus
prostate epithelium and hyperplasia of 20-week-old mice. Prostate epithelium, hyperplasia and
tumor Ki-67 representative stainings are shown in Fig 1J, 1K and 1L, respectively. There was a
significant increase in Ki-67 expression in prostate epithelium and hyperplasia of 8- compared
to 16- and 20-week-old mice (Table 9). There was a significant increase in Ki-67 expression in
prostate epithelium of 12- versus 16-week-old mice. There was a significant increase in Ki-67
expression in hyperplasia compared to prostate epithelium and tumor of 20-week-old mice.
Prostate epithelium, hyperplasia and tumor apoptosis representative stainings are shown in
Fig 1M, 1N and 1O, respectively. There was no significant difference in apoptosis in the cell
types within and between groups (Table 10).
Biomarker correlation with adjusted prostate severe lesion scores
Only one significant correlation between biomarkers and adjusted prostate severe lesion scores
was identified. Prostate 5αR1 levels were positively correlated with adjusted prostate most
severe lesion scores (Fig 2). Correlation between 5αR1 in prostate and adjusted prostate severe
lesion scores was compared in 8-, 12-, 16-, and 20-week-old mice and found to have a similar
trend in all groups, thus age did not appear to impact this correlation. Adjusted prostate severe
lesion scores was used because it combines lesion severity with an indication of its distribution
within a lobe [22].
Discussion
The raw and adjusted, mean most severe lesion scores were slightly increased in 20-week-old
mice compared to 20-week-old control C57BL/6 TRAMP x FVB mice in our previous study
[23], which may suggest that in this study, lesions were more severe or progressing faster.
Given that this study was conducted at the same time using littermates of that study, this
Table 6. 5α-reductase 1 expression in 8-, 12-, 16-, and 20-week-old C57BL/6 TRAMP x FVB mice. The values are the mean total 5α-reductase 1 probe
copies per tissue area (μm2) ± SEM in prostate epithelium, hyperplasia or tumor.
5α-reductase 1
Group n Prostate epithelium n Hyperplasia n Tumor
8-weeks 5 5.8 ± 2.5 5 5.4 ± 1.1 - —
12-weeks 4 18.7 ± 8.7 5 10.5 ± 4.1 2 16.8 ± 12.1
16-weeks 5 15.1 ± 5.3 5 6.7 ± 3.5 2 15.7 ± 5.1
20-weeks 2 22.4 ± 9.5 2 13.5 ± 5.6 4 15.8 ± 4.1
p < 0.05 vs. prostate epithelium, hyperplasia and tumor within and between groups. Data are multiplied by 1000.
https://doi.org/10.1371/journal.pone.0175874.t006
Table 7. 5α-reductase 2 expression in 8-, 12-, 16-, and 20-week-old C57BL/6 TRAMP x FVB mice. The values are the mean total 5α-reductase 2 probe
copies per tissue area (μm2) ± SEM in prostate epithelium, hyperplasia or tumor.
5α-reductase 2
Group n Prostate epithelium n Hyperplasia n Tumor
8-weeks 5 9.0 ± 4.7 5 3.8 ± 1.3 - —
12-weeks 5 12.2 ± 5.3 5 9.0 ± 4.6 2 12.7 ± 10.6
16-weeks 4 7.5 ± 2.6 4 6.9 ± 3.6 2 0.7
20-weeks 1 17.7 1 1.8 3 4.1 ± 1.6
p < 0.05 vs. prostate epithelium, hyperplasia and tumor within and between groups. Data are multiplied by 1000.
https://doi.org/10.1371/journal.pone.0175874.t007
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outcome was surprising. Overall GU weights, development and progression of prostate cancer
were similar to that reported previously [20,22,24], but contrary to another reported previously
[19]. We observed a notable increase in iliac lymph node metastases incidence with increasing
age.
5αR1 was predominantly expressed in prostate epithelium, while 5αR2 was highly ex-
pressed in both prostate epithelium and stroma consistent to expression in human prostate
[11,25]. 5αR1 levels in tumors were not statistically different from prostate epithelium and
hyperplasia, which is different than the significantly higher 5αR1 in human prostate cancer
compared to normal and/or hyperplastic prostate [11,26]. Although 5αR1 was increased in
high grade compared to low grade prostate cancer [27,28], this is the first study to report that
prostate 5αR1 levels are positively correlated with prostate most severe lesion scores. 5αR2 in
tumors was not statistically different between prostate epithelium and hyperplasia, which is
different than the higher 5αR2 levels in benign prostatic hyperplasia (BPH) compared to pros-
tate cancer [9]. Part of this difference might be the difference between BPH and prostate epi-
thelium and hyperplasia.
The marked decrease in AR expression in tumors compared to hyperplasia at 16 weeks,
and compared to prostate epithelium and hyperplasia at 20 weeks are consistent with weak to
negative AR levels in C57BL/6 TRAMP x FVB mice PD macroscopic tumors regardless of age
[29], weak AR staining in C57BL/6 TRAMP x FVB mice MD and PD tumors [20], or absence
of AR in most human PD tumors [30]. The loss of AR expression in tumors may be due to
them bypassing AR pathway for growth, or a reduction in the stability of AR protein that
decreases the AR protein levels to one difficult to detect immunohistologically [31].
The increased Ki-67 levels in hyperplasia, and the overall lack of difference between hyper-
plasia and tumor Ki-67 levels for all except the 20-week group may suggest that proliferation
does not vary much in the model at different time points. The lack of significant difference in
tumor cell proliferation between groups is consistent with results seen in the dorsal and ventral
Table 8. Androgen receptor (AR) expression in 8-, 12-, 16-, and 20-week-old C57BL/6 TRAMP x FVB mice. The values are the mean total AR positive
cells per tissue area (μm2) ± SEM in prostate epithelium, hyperplasia or tumor.
Androgen receptor
Group n Prostate epithelium n Hyperplasia n Tumor
8-weeks 5 5.9 ± 1.1 5 7.1 ± 0.7 - —
12-weeks 5 7.9 ± 0.6 5 8.5 ± 0.2 1 0.1
16-weeks 5 6.7 ± 0.51 5 9.3 ± 0.92 2 4.0 ± 0.21
20-weeks 5 7.5 ± 1.21 5 9.2 ± 1.31 5 1.5 ± 0.82
p < 0.05 vs. prostate epithelium, hyperplasia and tumor within group (number). Data are multiplied by 1000.
https://doi.org/10.1371/journal.pone.0175874.t008
Table 9. Ki-67 expression in 8-, 12-, 16-, and 20-week-old C57BL/6 TRAMP x FVB mice. The values are the mean total Ki-67 positive cells per tissue
area (μm2) ± SEM in prostate epithelium, hyperplasia or tumor.
Ki-67
Group n Prostate epithelium n Hyperplasia n Tumor
8-weeks 5 1.6 ± 0.5a 5 3.3 ± 0.9a - —
12-weeks 5 1.2 ± 0.4a,b 5 1.6 ± 0.6a,b 1 0.5
16-weeks 5 0.2 ± 0.2c 5 0.4 ± 0.3b 2 0.2 ± 0.1
20-weeks 5 0.3 ± 0.2b,c,1 5 1.2 ± 0.2b,2 5 0.3 ± 0.11
p < 0.05 vs. prostate epithelium, hyperplasia and tumor within (number) and between groups (letter). Data are multiplied by 1000.
https://doi.org/10.1371/journal.pone.0175874.t009
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prostate lobes of 10-, 16-, and 24-week-old TRAMP mice [32], and tumor between low-lyco-
pene diets at 12, 16, and 20 weeks of age in C57BL/6 TRAMP x FVB mice [24], but not consis-
tent with the significant decrease in tumor of 17-, 24-, and 36-week-old C57BL/6 TRAMP
mice with age [33]. All mice expressed Ki-67 in predominantly PD tumors, which is greater
than ~70% of C57BL/6 TRAMP x FVB mice that expressed Ki-67 in PD tumors in a previous
study [20].
Apoptosis was completely absent in the prostate epithelium, probably due to the strong
oncogenic pressure present in these mice with an SV40 Tag–induced disturbance in p53- and
Rb-regulated cell functions [18,34]. Higher apoptosis in hyperplasia compared to tumor is
consistent with elevated apoptosis in preneoplastic lesions [35]. Though not statistically signifi-
cant, increased tumor apoptosis with age is consistent with a similar finding in the dorsolateral
prostate of 17-, 24-, and 36-week-old C57BL/6 TRAMP mice [33]. Apoptosis was lower in
prostate epithelium than tumor which is not consistent with the progressive decrease in apo-
ptosis from BPH, high-grade PIN, to prostate cancer [36]. Conversely, there were no signifi-
cant differences in apoptosis in all lobes between low-lycopene diets at 12, 16, and 20 weeks of
age in C57BL/6 TRAMP x FVB mice [24].
There are limitations to this study that should be noted. We were unable to make some
comparisons due to the lack of replicates or loss of one or more cell types. This limited the
Table 10. Apoptosis expression in 8-, 12-, 16-, and 20-week-old C57BL/6 TRAMP x FVB mice. The values are the mean total apoptosis positive cells
per tissue area (μm2) ± SEM in prostate epithelium, hyperplasia or tumor.
Apoptosis
Group n Prostate epithelium n Hyperplasia n Tumor
8-weeks - — 5 0.4 ± 0.1 - —
12-weeks - — 5 0.8 ± 0.5 1 0.1
16-weeks - — 5 0.5 ± 0.2 2 0.2
20-weeks - — 4 0.1 ± 0.1 5 0.2 ± 0.1
p < 0.05 vs. prostate epithelium, hyperplasia and tumor within and between groups. Data are multiplied by 1000.
https://doi.org/10.1371/journal.pone.0175874.t010
Fig 2. Spearman correlation coefficient (r) between 5α-reductase 1 (5αR1) in prostate and adjusted
prostate most severe lesion scores. There was a significant positive correlation between 5α-reductase 1 in
prostate and adjusted prostate most severe lesion scores (r = 0.52; p = 0.04).
https://doi.org/10.1371/journal.pone.0175874.g002
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interpretation of the results. In addition, the fact that many of these tumors are of neuroendo-
crine origin suggests that results may be applicable to a subpopulation of patients with neuro-
endocrine disease [37], and while the TRAMP mouse promoter is driven by androgens, the
tumors derived from it are androgen-independent [15]. Despite these limitations, many of the
findings were consistent with results reported in humans. As such, decreased AR and 5αR2
along with increased 5αR1 in tumors may promote PIN and prostate cancer development,
thus warranting further investigation.
Supporting information
S1 File. This is data underlying the findings for genitourinary weight, raw and adjusted
mean most severe and most common lesion scores, histopathological analysis (most severe
and most common lesion), 5αR1, 5αR2, androgen receptor, Ki-67 and apoptosis, and
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